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Chapter 19
Commercial Products for Osteochondral 
Tissue Repair and Regeneration
Diana Bicho, Sandra Pina, Rui L. Reis, and J. Miguel Oliveira
Abstract The osteochondral tissue represents a complex structure composed of 
four interconnected structures, namely hyaline cartilage, a thin layer of calcified 
cartilage, subchondral bone, and cancellous bone. Due to the several difficulties 
associated with its repair and regeneration, researchers have developed several stud-
ies aiming to restore the native tissue, some of which had led to tissue-engineered 
commercial products. In this sense, this chapter discusses the good manufacturing 
practices, regulatory medical conditions and challenges on clinical translations that 
should be fulfilled regarding the safety and efficacy of the new commercialized 
products. Furthermore, we review the current osteochondral products that are cur-
rently being marketed and applied in the clinical setting, emphasizing the advan-
tages and difficulties of each one.
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19.1  Introduction
Treatment of bone and cartilage defects represents a current problem that needs to be 
solved. Although the present therapies are well established and effective for reduc-
ing pain, thus improving the patients’ quality of life, the hyaline or articular cartilage 
has a limited regeneration capacity, demanding new therapeutic options for com-
plete healing of the osteochondral (OC) lesions. In this sense, tissue engineered bio-
materials for OC application present some key challenges regarding their 
biocompatibility, bioactivity, biodegradation, and biomechanical properties. 
Additionally, the ion release of metallic materials and the reproducibility of the tech-
niques are also fundamental aspects to address [1]. Furthermore, the strategies 
applied need to present biodegradable with nontoxic degradation products of easy 
metabolization and excretion, well-regulated degradation kinetics and similar rate to 
native tissue. Similarly, the expected local or systemic immune responses should be 
controlled since it will affect significantly the implant–host integration. Most impor-
tantly, OC biomaterials should be able to mimic the extracellular matrix (ECM) and 
the complex mechanisms involved in the surrounding cells where the biomaterial 
will be applied [2]. The biomaterial chosen should be able to aid the cells to grow 
and proliferate at a similar natural rate, with an efficient gas and nutrients exchange 
[3]. Thus, the choice of the biomaterial is extremely important and needs to consider 
not only its chemical composition, but also its physical properties [4]. Specifically, 
in OC tissue engineering the mechanical properties must be able to bear the daily 
stress to which this tissue is subjected, as well as to support integration of the cells 
involved. Equally, the microstructure of the scaffold is essential for chondrogenesis 
and osteogenesis. Normally, it is believed that a superior cell ingrowth, improved 
transport of nutrient and vascular formation is related with high porosity (> 300 μm) 
[5] and interconnectivity (>100 μm) of scaffolds to allow a proper cell colonization 
[6]. In regards to osteoinductive potential, there has been extensive research with 
some good synthetic materials having emerged, for example hydroxyapatite (HA), 
octacalcium phosphate (OCP), and β-tricalcium phosphate (β-TCP). However, 
regardless of their ability to be integrated into host tissues, they present poor mechan-
ical properties, being therefore necessary to mix them with different materials that 
could overcome such limitations, and improve integration in OC lesions [7]. In addi-
tion, different natural and synthetic materials have been employed to engineer OC 
repair, presenting advantages and limitations. For instance, natural polymers are nor-
mally biocompatible and allow the interaction with cell receptors. However, safety 
concerns are usually an issue. In contrast, synthetic materials are more easily con-
trollable and reproducible but lack the cell- recognition signals [8]. Researchers have 
suggested these materials to be especially used in the regeneration of large OC 
defects and sometimes combined with cells, growth factors, and tissue grafts [9].
Beside these scientific advances, when trying to launch new medical products and 
technologies to the market, several regulatory medical conditions should be fulfilled 
regarding their safety and efficacy. Moreover, regulatory hurdles associated with the 
commercialization of new products are critical. Therefore, laboratory facilities, 
manufacturing practices and documentation related to products development should 
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follow strict requirements to ensure both the welfare of the individuals involved in 
the process and the reproducibility of the procedures. It is important to stress that all 
the directives involved in the manufacture and propagation of medical products and 
devices, can cause disagreements depending on the governmental administration 
involved. Among the multitude of options, Federal Food and Drug Administration 
(FDA) in the USA, and regional or centralized regulatory bodies like the European 
Medicines Agency (EMA) in the European Union (EU) are the most used. They are 
responsible for the development, assessment, and supervision of medicines [10]. 
Beyond this fact, it is also important to point out that the translations of the medical 
technologies into the clinic also rely on its nature, because cellular and acellular 
devices face different regulatory scrutiny in each country [11].
This chapter covers the general cares required for manufacturing tissue engineer-
ing and regenerative medicine (TERM) products. Particularly, it is focused the 
existing marketed products for OC tissue engineering and regeneration.
19.2  Good Manufacturing Practices and Regulatory Hurdles 
in Tissue-Engineered Products
Over the recent years, TERM has witnessed a rapid development that has motivated 
the marketing of novel products and with it some quality control procedures, and 
consistency and reproducibility guarantees. To assure that these conditions are 
being implemented, the FDA, EMA, and other world organizational committees are 
responsible to inspect the developers of commercial products. These organizations 
allow the implementation of standard procedures that extend away from individuals, 
research groups, and organizational procedures. It is their intention to have proto-
cols in place that are independent of the operators and/or equipment guaranteeing 
uniformity of the data [12].
Good manufacturing practices (GMP) are a series of regulations that ensure that 
diagnostics, the production of pharmaceutical and medical devices, are controlled 
according to defined quality standards. GMP refers to all up-to-date aspects of the 
production from materials and equipment to the training staff and hygiene [13]. 
Moreover, the use of cells and tissues of human origin for TERM products also need 
to answer the good tissue practices (GTP). Particularly, GTP focuses its require-
ments on the prevention of the initiation, diffusion, and spread of contagious dis-
eases besides ensuring uniformity, consistency, reliability, and reproducibility [14]. 
Following these lines, the description of a task or operation has to be performed in 
an identical manner and in compliance with appropriate regulation, as an approved 
standard operation procedure (SOP). Highly specific SOPs are usually required dur-
ing all phases of a manufacturing process, and therefore are used to control the 
manufacturing of TERM products. Companies must agree to operate under 
 harmonized guidelines across different geographic locations to assure that the best 
practices exist in every corner of the world. For instance, regarding TERM products 
using patient samples, companies need to pay attention to the appropriate ways to 
19 Commercial Products for Osteochondral Tissue Repair and Regeneration
418
transport them once the classification of the shipment is the key in defining the level 
of containment required [13]. Fortunately, the TERM field is at the front line in 
terms of harmonization of international regulatory agencies, mostly because of the 
use of human cells in therapy, which has lead a worldwide joint effort [15]. 
Nevertheless, it should be kept in mind that the introduction of cells in tissue- 
engineered materials has associated hazards such as teratoma formation, contami-
nation, immunogenicity, and insufficient cell adaptation. Thus, even though the 
materials used for tissue engineered strategies affect the regulatory process, cellular 
scaffolds pass through more regulatory hurdles to assure their safety.
19.3  Challenges in Clinical Translation and FDA Regulation
The programs for safety regulation vary widely by the type of product, its potential 
risks, and the regulatory powers granted to the agency. For example, the FDA regu-
lates almost every facet of prescription drugs, including testing, manufacturing, 
labeling, advertising, marketing, efficacy, and safety, yet FDA regulation of cosmet-
ics focuses primarily on labeling and safety. The FDA regulates most products with 
a set of published standards enforced by a modest number of facility inspections 
[16]. Each type of material is subjected to a different type of regulation based on its 
classification. Therefore, it is possible to characterize devices as “substantially 
equivalent” to currently accepted devices, allowing them to be more easily commer-
cialized [17]. Contrariwise, when using novel bioactive scaffolds it is necessary to 
deeply describe their degradation and safety profile in preclinical and clinical stud-
ies, which normally results in a 30% of the costs increment [11]. However, if possi-
ble, new materials with more refined features should be created for TERM 
applications despite the innumerous hurdles that ought to be addressed for eventual 
clinical success. The first aspect to keep in mind is the scientific basis and the patent-
ability of the technology. Furthermore, clinical studies should be carefully con-
ducted. Then, the company where the product has been developed needs to assure 
not only enough financial support but also the regulatory requirements for GMP in 
order to have reproducible products [12]. Finally, the market potential of the thera-
peutic solution, possible competitors, and target audience may be considered. 
Nevertheless, even with these concerns, TERM is experiencing a boost in the devel-
opment of new therapies for the treatment of chronic diseases and damaged tissues.
19.4  Commercially Available Products for Osteochondral 
Regeneration
The commercialization process of the scaffolds for implantation involves multiple 
stages of R&D replications before reaching the final approval from the government. 
R&D stages ensure safety and efficacy of the implants, which involve the produc-
tion of medical grade scaffolds followed by animal testing, under regulatory 
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approved conditions. Over the recent years, the concentrated research on TERM has 
resulted in few clinically approved therapeutics. Biomaterials applied in tissue 
regeneration are normally composed of a temporary three-dimensional (3D) sup-
port for the growth of cells that will regenerate a given injury, being then biode-
graded and substituted by the new tissue. In OC regeneration, different materials 
have been employed as templates for cell interactions and formation of ECM to 
support the newly formed tissue. However, the most commonly used technique con-
sists in designing bilayered scaffolds able to regenerate both cartilage and subchon-
dral bone [18]. Normally, autologous chondrocytes are seeded at the top of the 
scaffold and allows the application of a cell–scaffold implantation [19]. An alterna-
tive approach to this procedure uses two scaffolds from cartilage and bone assem-
bled either before or during implantation to assure OC regeneration [20].
At the present time, some commercial products have appeared. For example, 
Collagraft® (Nuecoll Inc.) consists of a mixture of collagen with HA and β-TCP in 
the form of granules. In previous studies, this product was used as subchondral sup-
port using chondrocytes harvested from rabbit articular cartilage. The animal model 
used survived through the regenerative process which occurred after 6 months pre-
senting the adequate features for bone integration, but not for cartilage [21]. On the 
other hand, the treatment of small OC defects is also possible with the collagen- 
based implant ChondroMimetic™ (TiGenix NV). This product is an off-the-shelf 
bilayer implant launched in the European market. The chondral layer is made of 
collagen and glycosaminoglycan while the osseous layer is composed of calcium 
phosphates. It showed to support the simultaneous natural repair mechanism of both 
articular cartilage and bone, following by implantation in patients [22]. Another 
collagen-based 3D scaffold to treat knee chondral or OC defects is MaioRegen® 
(Med&Care). This matrix mimics the entire osteo-cartilaginous tissue and is com-
posed of deantigenated type I equine collagen that resembles the cartilaginous tis-
sue, and magnesium enriched-HA for the subchondral bone structure [23]. 
Preclinical studies using 12 sheep proved that this biomaterial is able to promote 
bone and hyaline-like cartilage tissue restoration. Quantitative macroscopic analy-
sis showed absence of inflammation with some hyperemic synovium, but no syno-
vial hypertrophy or fibrosis was noted. The histological score evaluations confirmed 
the presence of a newly formed tissue and a good integration of scaffolds [24]. Also, 
clinical evaluation of knee chondral and OC lesions in 27 patients, during a 5-year 
follow-up scored clinical improvements. Magnetic resonance imaging (MRI) results 
demonstrated a complete graft integration in 78.3% of patients offering a good clini-
cal outcome for MaioRegen®. However, in another clinical investigation using knee 
and talar OC injuries, the biological response in vivo evaluated over 2.5 years show-
ing no improvements after the implantation of MaioRegen®. Radiographic results 
of computed tomography and MRI presented a complete defect filling, integration, 
and an intact articular surface after 2.5 years of implantation [25].
One of the products used as an injectable material, in the treatment of OA of the 
knee, is the Gel-One®, which is composed of a cross-linked hyaluronic acid hydrogel 
through a photo-gelation process [26]. This product was applied in a clinical study 
using 379 patients with OA, and a single injection allowed both the relief of the pain 
associated to this condition for 13 weeks, as well as physical improvements [27].
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BST-Cargel® (Piramal Life Sciences) has emerged as an advanced biodegradable 
and injectable chitosan hydrogel mixed with glycerophosphate and autologous 
blood to improve cartilage regeneration [28]. This off-the-shelf product can be used 
in conjunction with bone marrow cell stimulation by directly mixing blood from the 
patient with the biopolymer. This product has proved to be efficient in the initiation 
and amplification of the intrinsic wound healing processes of subchondral bone, as 
well as of the cartilage repair [28, 29]. An international randomized controlled trial 
with 80 patients was performed to compare the BST-Cargel® treatment with micro-
fractured untreated patients. The results showed to be effective in the mid-term car-
tilage repair, and after 5-year follow up the treatment resulted in a sustained and 
significantly superior quantity and quality of repaired tissue against the microfrac-
ture alone [30]. Another commercial approach used in the treatment of cartilage 
defects, consists of a resorbable and textile polyglycolic acid–hyaluronan (PGA/
hyaluronan) implant named Chondrotissue® (Biotissue). In preclinical studies with 
an ovine animal model it has shown improved tissue formation [31]. Clinical results 
with 5-year follow-up registered that this product had a good safety profile and pro-
vided a good filling of the chondral defects of the knee [32]. The effects of 
Chondrotissue® in patella defects of the cartilage were also evaluated by first debrid-
ing the damaged cartilage down to the subchondral bone. Then, the immersion of 
the implant in venous blood allows an enhanced MSC recruitment and integration 
leading to the improvement of the symptoms and no intraoperative or postoperative 
complications [33]. Chondrocushion (Advanced Bio Surfaces, Inc) made of bipha-
sic polyurethane cylinders is a synthethic product evaluated for cartilage applica-
tion. This biomaterial presents some potential disadvantages related with the lack of 
porosity which impedes tissue ingrowth and replacement [34]. Other drawbacks of 
this type of product include the displacement of the implant site and the release of 
potentially toxic by-products that can cause inflammation and cell death [22, 35]. 
Another product within this category is SaluCartilage™ (SaluMedica), a biocom-
patible and hydrophilic cylindrical device consisting of a polyvinyl alcohol hydro-
gel. This material mimics human cartilage in terms of water proportions and has 
been evaluated as a synthetic surface for the replacement of damaged cartilage. 
There is no evidence of inflammatory reaction or osteolysis associated with this 
implant [35]. Correspondingly, clinical results showed improvement of the chondral 
defects, but the hydrogel showed inadequate connection to the bone and risk of 
dislocation [36].
TruGraft™ (Osteobiologics) is a poly(lactic-co-glycolic) acid (PLGA) granulate 
used as a bone void filler, and has shown to support osteoblast proliferation and dif-
ferentiation proved by high alkaline phosphatase activity and deposition of a miner-
alized matrix used in OC repair [37]. Bioseed®-C (Biotissue Technologies GmbH) 
is a bioresorbable scaffold for OC composed of fibrin, PLA and polyglycoic acid 
(PGA) copolymer, and polydioxanone embedding chondrocytes [38]. This product 
was preclinically evaluated on an equine animal model of full thickness cartilage 
defects and showed capacity to be integrated while promoting the formation of car-
tilaginous tissue [39]. These promising results made the testing of this product pro-
ceed into humans with posttraumatic and degenerative cartilage defects of the knee 
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[40, 41]. It was reported that most of the grafts were able of completely fill the 
defects and formed tough hyaline-like cartilage, being well integrated into the tissue 
with good connection with the articular cartilage and the subchondral bone.
Feeding the importance of subchondral bone in the maintenance of articular car-
tilage, researchers have been developing some biphasic products in order to mimic 
both structures. These bilayered scaffolds have different characteristics to address 
different biological and functional requirements of both bone and cartilage, which 
are essential in the treatment of OC defects [23]. Accordingly, some commercial 
biphasic scaffolds are available in the market. For example, a product derived from 
natural sources for OC application, is Agili-C™ (CartiHeal) composed of calcium 
carbonate for the bone region, and aragonite and hyaluronic acid for the cartilage 
part (Fig.  19.1a). Results, after 12  months of implantation in a caprine animal 
model, showed an improvement in terms of cartilage repair and osteointegration 
with a reduction of the symptoms (limited motion, swelling of the joint, and pain). 
The bone phase of the implant shows a structure similar to natural bone presenting 
high pore interconnectivity essential for blood vessels [42, 43]. In contrast, the 
chondral phase rich in hyaluronic acid helps the ECM of the cartilage to be main-
tained with their proper characteristics. Kensey Nash Corporation started develop-
ing an acellular Cartilage Repair Device (CRD) to tackle primary defects of the 
articular cartilage in the joints, the OsseoFit® plug. This product was indicated to 
support the regeneration of hyaline cartilage and subchondral bone by promoting 
the correct cellular morphology, and structural organization during the healing pro-
cess. The OsseoFit® plug is composed of a bioresorbable biphasic scaffold of col-
lagen type-I fibrils, to simulate the cartilage, and 80% β-TCP + 20% polylactic acid 
(PLA) for the subchondral bone phase. A study using OsseoFit® applied in 10 plugs 
on the medial femoral condyle and on the lateral femoral condyle displayed a reduc-
tion in height of the material and the integration of the product on the surrounding 
native cartilage [19]. HYAFF® (Fidia Advanced Biopolymers) is a biodegradable scaf-
fold used for repair of chondral and OC lesions. It is composed of purified hyaluro-
nan esterified in its glucuronic acid group with distinct types of alcohols (Fig. 19.1b). 
Fig. 19.1 Commercial biphasic scaffolds for osteochondral repair/regeneration: (a) Agili-C™ 
(reprinted with permission from [50]); (b) HYAFF™ (reprinted with permission from [51]. 
Copyright© 2015, Springer Nature) and (c) Trufit™
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In vitro degradation profile of HYAFF® 11 suggested that the hyaluronan esters 
undergo spontaneous deesterification in an aqueous environment, meaning a good 
integration in the biological tissues [44]. Also, in vivo studies showed a minimal 
response after the first month of implantation, and no evidence of toxicity during the 
1-year study following implantation. HYAFF® 11 scaffolds present the advantage of 
having good cell adhesiveness even without coating and surface conditioning [45]. 
TruFit® (Smith & Nephew) is another product used in OC applications (Fig. 19.1c) 
that consists of calcium phosphate and PLGA. This product presented good filling 
of OC defects, good integration in the native cartilage, and histological assays that 
showed a high percentage of hyaline cartilage formation, and good bone renovation 
after implantation in the femoral condyles and trochleae of goat defects [46]. 
Originally, this plug was designed as an alternative treatment for OC autologous 
transplantation, but in Europe has also been applied for acute focal articular carti-
lage and OC defects [47, 48]. Conversely, another work showed a comparative 
study between patients undergoing mosaicplasty (harvest and transplant of plugs of 
bone and cartilage from one place to another) and patients implanted with TruFit® 
showed no improvement in applying this product in comparison to the other proce-
dure [49].
In order to establish a complete regenerative engineered strategy for TERM 
application, the use of cellular scaffolds has been proposed. The inclusion of liv-
ing cells into the scaffolds enables real time growth factors, cytokines and matrix 
proteins which will accelerate the regenerative process. However, this technology 
also brings many complications besides the inevitable high costs, complexity of 
manufacture, sterility, preservation and regulatory issues. Currently, the applica-
tion of cells without a scaffold has undergone several clinical studies showing that 
integration with the host tissue remains a problem [52]. This fact had led to the 
development of grafts combining living cells with biomaterials ex vivo allowing 
the construction of a 3D structure to be implanted in the living organism. 
Nevertheless, the type of cells and their quantity will help to set the mechanical 
and biochemical characteristics of the graft [53, 54]. The marketed product 
Osteocel® Plus (NuVasive®) is an example of a cell-based bone graft. It contains 
native MSCs and osteoprogenitor cells combined with an osteoconductive demin-
eralized bone matrix (DBM), and cancellous bone, presenting osteogenic capac-
ity. Promising experiences with this material have been reported for several 
applications, including lumbar [55], as well as periodontal [56], foot and ankle 
defects [57].
On the other side, demineralized matrices from human donors are also applied 
as optimal biomaterials. An example is Dynagraft®, a DBM combined with polox-
amer, the nonionic triblock copolymer (GenSci Regeneration Sciences). This graft 
is moldable, packable and can be mixed with grafting materials being resistant to 
irrigation. Additionally, hyaluronate (i.e., DBX®, Synthes), glycerol (Grafton®, 
Osteotech, USA), and calcium sulfate (Allomatrix®, Wright Medical Technology) 
have also been applied with DBM and are also being commercialized [58, 59]. 
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Commercially available cartilage graft BioCartilage® (Arthrex) provides a simple 
and inexpensive method to use extracellular cartilage matrix that has been dehy-
drated and micronized. It provides a proper scaffold to correct microfracture 
defects of articular cartilage, providing the appropriate biochemical signals, 
including collagen type II, cartilage matrix elements, and growth factors [60]. One 
of the few FDA approved ACT products is Carticel® (genzyme), which a cellular 
graft of autologous cultured cells derived from in vitro expansion of chondrocytes 
of femoral articular cartilage from the patient. The application of Carticel® in 
young patients has originated a cartilage tissue containing predominately collagen 
type II but lacking total host integration and alignment with the surrounding car-
tilage [61]. Hyalograft® C is another commercially available matrix to assist chon-
drocyte implantation. This product is composed of a hyaluronic acid-based 
cartilage graft in combination with autologous isolated and enriched chondro-
cytes. The clinical data of the application of this product showed improvements in 
91.5% of the patients [62, 63]. The use of minced articular cartilage (autologous 
or allogeneic) defects is being explored for cartilage repair in OC defects. The 
off-the-shelf human tissue allograft DeNovo NT (Zimmer), consisting of juvenile 
hyaline cartilage pieces with viable chondrocytes, has emerged. This commercial 
product is intended to finds uses in lesions of articular cartilage. When implanting 
DeNovo NT, the debridement of the fibrous and calcified tissue of the defect 
should be performed without violating the subchondral bone layer. Then the 
implant is added to the lesion site and using fibrin glue will help the tissue to be 
maintained in place [64, 65]. Recently, this juvenile particulate cartilage has been 
employed in patellar lesions with success. It has been demonstrated that the repair 
hyaline cartilage is performed by integration with the surrounding tissue showing 
a good recovery and improvement of the movements and reducing the pain associ-
ated with OC lesions [66]. Another alternative is the OC allograft Chondrofix® 
(Zimmer®) composed of decellularized cadaveric human joints consisting of hya-
line cartilage and cancellous bone [67]. A case report of Chondrofix® implanted in 
a large full-thickness OC defect demonstrated to be completely incorporated by 
the bone without articular cartilage margins and restoring the native femoral con-
dylar radius of curvature [68]. Nevertheless, when working with these types of 
materials, the risk of disease transmission or immunogenicity still remains. 
Moreover, they can be quite brittle leading to the accumulation of microfractures 
during the remodeling phase [69].
The available commercial products aforementioned show that there is still much 
research that needs to be done to create new therapies to significantly increase the 
regenerative capacity of OC structure. A summary of these commercialized prod-
ucts for bone, cartilage, and OC tissue regeneration is presented in Table 19.1.
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19.5  Concluding Remarks and Future Trends
Several attempts are being made to mimic in vivo situations, and in fact enormous 
advances as regards not only to OC tissues but also to other tissues of the human 
body have been made. Herein, in this chapter we describe some commercial OC 
approaches, particularly based on 3D scaffolds envisioned to support newly formed 
tissues. The presented scaffolds are either biphasic, injectable hydrogels or decel-
lularized matrices, and their outcomes reinforce the ideal basic requirements for the 
design of OC constructs aiming at tissue repair and regeneration. Such necessities 
include porosity, mechanical strength, biocompatibility, bioactivity, biodegradabil-
ity, bio-integration, and proper cell proliferation and differentiation. Besides, due to 
Table 19.1 Commercial products for the repair and regeneration of bone, cartilage, and OC 
defects
Product Manufacturer Composition Bioresorbable Applications
Chondromimetic™ TiGenix NV Collagen, GAG, and CaP ✓ OC
Trufit™ Smith & 
Nephew
Calcium sulfate, PLGA/
PGA
✓ OC
MaioRegen® Med&Care Collagen type I and 
magnesium enriched-HA
✓ OC
OsseoFit® plug Type I collagen, and 80% 
β-TCP + 20% PLA
✓ OC
BST-Cargel® Piramal Life 
Sciences
Chitosan gel, 
glycerophosphate, and 
autologous blood
n.d. OC
Bioseed®-C Biotissue 
Technologies 
GmbH
PLA/PGA n.d. OC
Agili-C™ CartiHeal Calcium carbonate and 
aragonite with hyaluronic 
acid.
✓ OC
Collagraft® Nuecoll Inc Collagen with granules 
of HA and β-TCP
✓ OC
Chondrotissue® Biotissue PGA/hyaluronan ✓ Cartilage
HYAFF® 11 Anika 
Therapeutics
Hyaluronan ✓ Cartilage and 
OC
Chondrocushion Advanced Bio 
Surfaces, Inc
Polyurethane No Cartilage
BST-Cargel® Piramal Life 
Sciences
Chitosan with glycerol 
phosphate and 
autologous blood
✓ Cartilage
SaluCartilage™ SaluMedica Polyvinyl alcohol 
hydrogel
✓ Cartilage
Gel-One® Zimmer Hyaluronic acid n.d. Knee OA
n.d not defined, GAG glycosaminoglycans, CaP calcium phosphates, OC osteochondral, PLGA 
poly(lactic-co-glycolic) acid, HA hydroxyapatite, PLA polylactic acid, PGA polyglycolic acid, OA 
osteoarthritis
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its medical nature, new commercial products must undergo laborious testing, as 
demanded by regulatory approval bodies, before their use in humans. Therefore, 
some prospective improvements are under investigation to create better OC prod-
ucts. In this front, researchers are trying to enhance cell attachment to scaffolds 
using cell-adhesive ligands, and changing cell morphology, alignment, and pheno-
type, by varying the topographic surface of the scaffolds or even by mechanobio-
logical stimulation of cells. Growth factors can also be incorporated directly into the 
scaffolds to help cells to differentiate, but immunomodulatory molecules are also an 
option to help to control inflammation towards the regenerative process. In the end, 
the final purpose is to create a scaffold that entirely mimics the ECM of OC tissue, 
having simultaneously proper mechanical properties, biochemical cues and the 
appropriate degradation profile, providing the ideal conditions for tissue growth.
Acknowledgments The authors acknowledge the project FROnTHERA (NORTE-01-0145- 
FEDER-000023), supported by Norte Portugal Regional Operational Programme (NORTE 2020), 
under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development 
Fund (ERDF). The authors would also like to acknowledge H2020-MSCA-RISE program, as this 
work is part of developments carried out in BAMOS project, funded by the European Union’s 
Horizon 2020 research and innovation program under grant agreement N° 734156. The financial 
support from the Portuguese Foundation for Science and Technology under the program 
Investigador FCT 2012 and 2015 (IF/00423/2012 and IF/01285/2015) is also greatly 
acknowledged.
References
 1. Bose S, Roy M, Bandyopadhyay A (2012) Recent advances in bone tissue engineering scaf-
folds. Trends Biotechnol 30:546–554. https://doi.org/10.1016/j.tibtech.2012.07.005
 2. Benders KEM, van Weeren PR, Badylak SF et  al (2013) Extracellular matrix scaffolds for 
cartilage and bone regeneration. Trends Biotechnol 31:169–176. https://doi.org/10.1016/j.
tibtech.2012.12.004
 3. Oliveira JT, Reis RL (2011) Polysaccharide-based materials for cartilage tissue engineering 
applications. J Tissue Eng Regen Med 5:421–436. https://doi.org/10.1002/term.335
 4. Ge Z, Jin Z, Cao T (2008) Manufacture of degradable polymeric scaffolds for bone regenera-
tion. Biomed Mater 3:22001. https://doi.org/10.1088/1748-6041/3/2/022001
 5. Karageorgiou V, Kaplan D (2005) Porosity of 3D biomaterial scaffolds and osteogenesis. 
Biomaterials 26:5474–5491. https://doi.org/10.1016/j.biomaterials.2005.02.002
 6. Habibovic P, Yuan H, van der Valk CM et al (2005) 3D microenvironment as essential element 
for osteoinduction by biomaterials. Biomaterials 26:3565–3575. https://doi.org/10.1016/j.
biomaterials.2004.09.056
 7. Pina S, Oliveira JM, Reis RL (2015) Natural-based nanocomposites for bone tissue engineer-
ing and regenerative medicine: a review. Adv Mater 27:1143–1169. https://doi.org/10.1002/
adma.201403354
 8. Canadas RF, Pina S, Marques AP et al (2016) Cartilage and bone regeneration—how close are 
we to bedside? In: Transl. Regen. Med. to Clin. Elsevier, Amsterdam, pp 89–106
 9. Giannoudis PV, Dinopoulos H, Tsiridis E (2005) Bone substitutes: an update. Injury 36:S20–
S27. https://doi.org/10.1016/j.injury.2005.07.029
 10. Van Norman GA (2016) Drugs and devices: comparison of European and U.S. approval pro-
cesses. JACC Basic Transl Sci 1:399–412. https://doi.org/10.1016/j.jacbts.2016.06.003
19 Commercial Products for Osteochondral Tissue Repair and Regeneration
426
 11. Webber MJ, Khan OF, Sydlik SA et  al (2014) A perspective on the clinical translation of 
scaffolds for tissue engineering. Ann Biomed Eng 43:641–656. https://doi.org/10.1007/
s10439-014-1104-7
 12. Dodson BP, Levine AD (2015) Challenges in the translation and commercialization of cell 
therapies. BMC Biotechnol 15:70. https://doi.org/10.1186/s12896-015-0190-4
 13. Basu J, Ludlow JW (2012) Regulatory and quality control. Dev Tissue Eng Regen Med Prod 
A Pract Approach 125–148. https://doi.org/10.1533/9781908818119.125
 14. Idowu B, Di Silvio L (2013) Principles of good laboratory practice (GLP) for in  vitro 
cell culture applications. Stand Cell Tissue Eng Methods Protoc 127–147. https://doi.
org/10.1533/9780857098726.2.127
 15. Gálvez P, Clares B, Hmadcha A et al (2013) Development of a cell-based medicinal product: 
regulatory structures in the European Union. Br Med Bull 105:85–105. https://doi.org/10.1093/
bmb/lds036
 16. Tyler RS (2013) The goals of FDA regulation and the challenges of meeting them. Health 
Matrix Clevel 22:423–431
 17. Lewin A (2012) Medical device innovation in America: tensions between food and drug law 
and patent law. Harv J Law Technol 26
 18. Dormer NH, Berkland CJ, Detamore MS (2010) Emerging techniques in stratified designs and 
continuous gradients for tissue engineering of interfaces. Ann Biomed Eng 38:2121–2141. 
https://doi.org/10.1007/s10439-010-0033-3
 19. Elguizaoui S, Flanigan DC, Harris JD et al (2012) Proud osteochondral autograft versus syn-
thetic plugs—contact pressures with cyclical loading in a bovine knee model. Knee 19:812–
817. https://doi.org/10.1016/j.knee.2012.03.008
 20. Swieszkowski W, Tuan BHS, Kurzydlowski KJ, Hutmacher DW (2007) Repair and regen-
eration of osteochondral defects in the articular joints. Biomol Eng 24:489–495. https://doi.
org/10.1016/j.bioeng.2007.07.014
 21. Schaefer D, Martin I, Jundt G et al (2002) Tissue-engineered composites for the repair of large 
osteochondral defects. Arthritis Rheum 46:2524–2534. https://doi.org/10.1002/art.10493
 22. Getgood A, Henson F, Skelton C et al (2014) Osteochondral tissue engineering using a bipha-
sic collagen/GAG scaffold containing rhFGF18 or BMP-7 in an ovine model. J Exp Orthop 
1:13. https://doi.org/10.1186/s40634-014-0013-x
 23. Kon E, Delcogliano M, Filardo G et al (2009) Novel nano-composite multi-layered biomate-
rial for the treatment of multifocal degenerative cartilage lesions. Knee Surg Sport Traumatol 
Arthrosc 17:1312–1315. https://doi.org/10.1007/s00167-009-0819-8
 24. Kon E, Delcogliano M, Filardo G et al (2010) Orderly osteochondral regeneration in a sheep 
model using a novel nano-composite multilayered biomaterial. J Orthop Res 28:n/a. https://
doi.org/10.1002/jor.20958
 25. Christensen BB, Foldager CB, Jensen J et al (2016) Poor osteochondral repair by a biomimetic 
collagen scaffold: 1- to 3-year clinical and radiological follow-up. Knee Surg Sport Traumatol 
Arthrosc 24:2380–2387. https://doi.org/10.1007/s00167-015-3538-3
 26. Ishikawa M, Yoshioka K, Urano K et al (2014) Biocompatibility of cross-linked hyaluronate 
(Gel-200) for the treatment of knee osteoarthritis. Osteoarthr Cartil 22:1902–1909. https://doi.
org/10.1016/j.joca.2014.08.002
 27. Strand V, Baraf HSB, Lavin PT et al (2012) A multicenter, randomized controlled trial compar-
ing a single intra-articular injection of Gel-200,?a?new cross-linked formulation of hyaluronic 
acid, to phosphate buffered saline for treatment of osteoarthritis of the knee. Osteoarthr Cartil 
20:350–356. https://doi.org/10.1016/j.joca.2012.01.013
 28. Stanish WD, McCormack R, Forriol F et al (2013) Novel scaffold-based BST-CarGel treat-
ment results in superior cartilage repair compared with microfracture in a randomized con-
trolled trial. J Bone Jt Surg Am 95:1640–1650. https://doi.org/10.2106/JBJS.L.01345
 29. Shive MS, Hoemann CD, Restrepo A et al (2006) BST-CarGel: in situ chondroinduction for 
cartilage repair. Oper Tech Orthop 16:271–278. https://doi.org/10.1053/j.oto.2006.08.001
 30. Shive MS, Stanish WD, McCormack R et al (2015) BST-CarGel® treatment maintains car-
tilage repair superiority over microfracture at 5 years in a multicenter randomized controlled 
trial. Cartilage 6:62–72. https://doi.org/10.1177/1947603514562064
D. Bicho et al.
427
 31. Erggelet C, Endres M, Neumann K et al (2009) Formation of cartilage repair tissue in articu-
lar cartilage defects pretreated with microfracture and covered with cell-free polymer-based 
implants. J Orthop Res 27:1353–1360. https://doi.org/10.1002/jor.20879
 32. Siclari A, Mascaro G, Gentili C et al (2014) Cartilage repair in the knee with subchondral drill-
ing augmented with a platelet-rich plasma-immersed polymer-based implant. Knee Surg Sport 
Traumatol Arthrosc 22:1225–1234. https://doi.org/10.1007/s00167-013-2484-1
 33. Becher C, Ettinger M, Ezechieli M et al (2015) Repair of retropatellar cartilage defects in the 
knee with microfracture and a cell-free polymer-based implant. Arch Orthop Trauma Surg 
135:1003–1010. https://doi.org/10.1007/s00402-015-2235-5
 34. McNickle AG, Provencher MT, Cole BJ (2008) Overview of Existing Cartilage 
Repair Technology. Sports Med Arthrosc 16:196–201. https://doi.org/10.1097/
JSA.0b013e31818cdb82
 35. Falez F, Sciarretta FV (2015) Treatment of osteochondral symptomatic defects of the knee 
with salucartilage. Orthop Proc 87-B
 36. Lange J, Follak N, Nowotny T, Merk H (2006) Ergebnisse der SaluCartilage-implantation 
bei viertgradigen Knorpelschäden im Bereich des Kniegelenks. Unfallchirurg 109:193–199. 
https://doi.org/10.1007/s00113-005-1025-x
 37. Ishaug-Riley SL, Crane-Kruger GM, Yaszemski MJ, Mikos AG (1998) Three-dimensional 
culture of rat calvarial osteoblasts in porous biodegradable polymers. Biomaterials 19:1405–
1412. https://doi.org/10.1016/S0142-9612(98)00021-0
 38. Demoor M, Ollitrault D, Gomez-Leduc T et al (2014) Cartilage tissue engineering: Molecular 
control of chondrocyte differentiation for proper cartilage matrix reconstruction. Biochim 
Biophys Acta Gen Subj 1840:2414–2440. https://doi.org/10.1016/j.bbagen.2014.02.030
 39. Barnewitz D, Endres M, Krüger I et al (2006) Treatment of articular cartilage defects in horses 
with polymer-based cartilage tissue engineering grafts. Biomaterials 27:2882–2889. https://
doi.org/10.1016/j.biomaterials.2006.01.008
 40. Kreuz PC, Müller S, Ossendorf C et al (2009) Treatment of focal degenerative cartilage defects 
with polymer-based autologous chondrocyte grafts: four-year clinical results. Arthritis Res 
Ther 11:R33. https://doi.org/10.1186/ar2638
 41. Ossendorf C, Kaps C, Kreuz PC et al (2007) Treatment of posttraumatic and focal osteoar-
thritic cartilage defects of the knee with autologous polymer-based three-dimensional chon-
drocyte grafts: 2-year clinical results. Arthritis Res Ther 9:R41. https://doi.org/10.1186/ar2180
 42. Guillemin G, Patat J-L, Fournie J, Chetail M (1987) The use of coral as a bone graft substitute. 
J Biomed Mater Res 21:557–567. https://doi.org/10.1002/jbm.820210503
 43. Kon E, Filardo G, Shani J et al (2015) Osteochondral regeneration with a novel aragonite- 
hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg 
Res 10:81. https://doi.org/10.1186/s13018-015-0211-y
 44. Zhong SP, Campoccia D, Doherty PJ et al (1994) Biodegradation of hyaluronic acid deriva-
tives by hyaluronidase. Biomaterials 15:359–365
 45. Campoccia D, Doherty P, Radice M et  al (1998) Semisynthetic resorbable materi-
als from hyaluronan esterification. Biomaterials 19:2101–2127. https://doi.org/10.1016/
S0142-9612(98)00042-8
 46. Iii RJW, Gamradt SC, Williams RJ (2008) Articular cartilage repair using a resorbable matrix 
scaffold. Instr Course Lect 57:563–571
 47. Melton JT, Wilson AJ, Chapman-Sheath P, Cossey AJ (2010) TruFit CB ® bone plug: chondral 
repair, scaffold design, surgical technique and early experiences. Expert Rev Med Devices 
7:333–341. https://doi.org/10.1586/erd.10.15
 48. Carmont MR, Carey-Smith R, Saithna A et  al (2009) Delayed Incorporation of a TruFit 
Plug: perseverance is recommended. Arthrosc J Arthrosc Relat Surg 25:810–814. https://doi.
org/10.1016/j.arthro.2009.01.023
 49. Hindle P, Hendry JL, Keating JF, Biant LC (2014) Autologous osteochondral mosaicplasty or 
TruFit® plugs for cartilage repair. Knee Surg Sport Traumatol Arthrosc 22:1235–1240. https://
doi.org/10.1007/s00167-013-2493-0
 50. Kon E, Filardo G, Perdisa F et al (2014) Clinical results of multilayered biomaterials for osteo-
chondral regeneration. J Exp Orthop 1:10. https://doi.org/10.1186/s40634-014-0010-0
19 Commercial Products for Osteochondral Tissue Repair and Regeneration
428
 51. Buda R, Vannini F, Castagnini F et al (2015) Regenerative treatment in osteochondral lesions 
of the talus: autologous chondrocyte implantation versus one-step bone marrow derived cells 
transplantation. Int Orthop 39:893–900. https://doi.org/10.1007/s00264-015-2685-y
 52. Worthen J, Waterman BR, Davidson PA, Lubowitz JH (2012) Limitations and sources of bias 
in clinical knee cartilage research. Arthrosc J Arthrosc Relat Surg 28:1315–1325. https://doi.
org/10.1016/j.arthro.2012.02.022
 53. Bertolo A, Mehr M, Aebli N et al (2012) Influence of different commercial scaffolds on the 
in vitro differentiation of human mesenchymal stem cells to nucleus pulposus-like cells. Eur 
Spine J 21(Suppl 6):S826–S838. https://doi.org/10.1007/s00586-011-1975-3
 54. Chen RR, Mooney DJ (2003) Polymeric growth factor delivery strategies for tissue engineer-
ing. Pharm Res 20:1103–1112. https://doi.org/10.1023/A:1025034925152
 55. Ammerman JM, Libricz J, Ammerman MD (2013) The role of Osteocel Plus as a fusion sub-
strate in minimally invasive instrumented transforaminal lumbar interbody fusion. Clin Neurol 
Neurosurg 115:991–994. https://doi.org/10.1016/j.clineuro.2012.10.013
 56. McAllister BS (2011) Stem cell-containing allograft matrix enhances periodontal regenera-
tion: case presentations. Int J Periodontics Restorative Dent 31:149–155
 57. Scott RT, Hyer CF (2013) Role of cellular allograft containing mesenchymal stem cells in high- 
risk foot and ankle reconstructions. J  Foot Ankle Surg 52:32–35. https://doi.org/10.1053/j.
jfas.2012.09.004
 58. Dhandayuthapani B, Yoshida Y, Maekawa T, Kumar DS (2011) Polymeric scaffolds in tissue 
engineering application: a review. Int J Polym Sci. https://doi.org/10.1155/2011/290602
 59. Drosos GI (2015) Use of demineralized bone matrix in the extremities. World J Orthop 6:269. 
https://doi.org/10.5312/wjo.v6.i2.269
 60. Abrams GD, Mall NA, Fortier LA et al (2013) BioCartilage: background and operative tech-
nique. Oper Tech Sports Med 21:116–124. https://doi.org/10.1053/j.otsm.2013.03.008
 61. Kurkijärvi JE, Mattila L, Ojala RO et  al (2007) Evaluation of cartilage repair in the distal 
femur after autologous chondrocyte transplantation using T2 relaxation time and dGEM-
RIC. Osteoarthr Cartil 15:372–378. https://doi.org/10.1016/j.joca.2006.10.001
 62. Gobbi A, Kon E, Berruto M et al (2009) Patellofemoral full-thickness chondral defects treated 
with second-generation autologous chondrocyte implantation. Am J  Sports Med 37:1083–
1092. https://doi.org/10.1177/0363546509331419
 63. Marcacci M, Berruto M, Brocchetta D, et  al (2005) Articular cartilage engineering with 
hyalograft(R) C: 3-year clinical results. [Report]. Clin Orthop Relat Res 96–105
 64. Tompkins M, Adkisson HD, Bonner KF (2013) DeNovo NT allograft. Oper Tech Sports Med 
21:82–89. https://doi.org/10.1053/j.otsm.2013.03.005
 65. Kruse DL, Ng A, Paden M, Stone PA (2012) Arthroscopic de novo NT? juvenile allograft 
cartilage implantation in the talus: a case presentation. J Foot Ankle Surg 51:218–221. https://
doi.org/10.1053/j.jfas.2011.10.027
 66. Buckwalter JA, Bowman GN, Albright JP et al (2014) Clinical outcomes of patellar chondral 
lesions treated with juvenile particulated cartilage allografts. Iowa Orthop J 34:44–49
 67. Gomoll AH (2013) Osteochondral allograft transplantation using the chondrofix implant. Oper 
Tech Sports Med 21:90–94. https://doi.org/10.1053/j.otsm.2013.03.002
 68. Reynolds KL, Bishai SK (2014) In situ evaluation of chondrofix(registered trademark) osteo-
chondral allograft 25 months following implantation: a case report. Osteoarthr Cartil 22:S155–
S156. https://doi.org/10.1016/j.joca.2014.02.288
 69. Horton MT, Pulido PA, McCauley JC, Bugbee WD (2013) Revision osteochondral allograft 
transplantations. Am J Sports Med 41:2507–2511. https://doi.org/10.1177/0363546513500628
D. Bicho et al.
